Roche Racks Up Another RoActemra Green Light To Boost Revenues
Executive Summary
The Swiss giant's blockbuster is the first non-steroid therapy approved in Europe for giant cell arteritis and the first major advance in treatment for over 50 years.
You may also be interested in...
Roche’s Gazyvaro Is Fifth Drug To Enter UK Cancer Drugs Fund
Roche’s Gazyvaro is the fifth drug to be recommended by UK HTA body NICE for use on an interim fund that gives manufacturers more time to gather evidence to prove their drugs are cost-effective and win long-term funding on the National Health Service.
Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates
The latest immunology drug development news and highlights from our FDA Performance Tracker.
Sobi Ramps Up In Rare Diseases With Apellis Deal
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports